|Articles|January 28, 2015

Segment 7: Guidelines for Diagnostic Test Use

The panelists discuss guidelines for diagnostic test use and the biggest challenge from a payer standpoint.

Francisco J. Esteva, MD, PhD, and Daniel F. Hayes, MD, discuss guidelines for diagnostic test use from the National Comprehensive Cancer Network and the American Society of Clinical Oncology and the differences in how each organization approached the development of guidelines.

John L. Fox, MD, added that the biggest challenges with guidelines are the underuse and overuse of diagnostics—the former being a larger issue than the latter. From a payer vantage, tests that are well validated and have clinical utility should be done and they are willing to pay because the high cost of patients receiving an inappropriate therapy is an avoidable expense.

“So we’re encouraging testing and making sure that patients are appropriate for therapy,” he said.


Related to this article

Anthony Stein, MD | Image: City of Hope
At an AJMC® Stakeholder Interchange in Los Angeles, leukemia specialists described a region where hospital formularies push menin inhibitor starts into the clinic, emergency department (ED) physicians may not recognize differentiation syndrome, and capitated insurance contracts steer some patients with acute myeloid leukemia away from academic centers.